ID   PLPL9_HUMAN             Reviewed;         806 AA.
AC   O60733; A8K597; B0QYE8; O75645; Q8N452; Q9UG29; Q9UIT0; Q9Y671;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   10-MAY-2017, entry version 174.
DE   RecName: Full=85/88 kDa calcium-independent phospholipase A2;
DE            Short=CaI-PLA2;
DE            EC=3.1.1.4;
DE   AltName: Full=Group VI phospholipase A2;
DE            Short=GVI PLA2;
DE   AltName: Full=Intracellular membrane-associated calcium-independent phospholipase A2 beta;
DE            Short=iPLA2-beta;
DE   AltName: Full=Patatin-like phospholipase domain-containing protein 9;
DE            Short=PNPLA9;
GN   Name=PLA2G6; Synonyms=PLPLA9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LH-IPLA2; ANKYRIN-IPLA2-1 AND
RP   ANKYRIN-IPLA2-2).
RC   TISSUE=B-cell, and Testis;
RX   PubMed=9417066; DOI=10.1074/jbc.273.1.207;
RA   Larsson P.K.A., Claesson H.-E., Kennedy B.P.;
RT   "Multiple splice variants of the human calcium-independent
RT   phospholipase A2 and their effect on enzyme activity.";
RL   J. Biol. Chem. 273:207-214(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS LH-IPLA2 AND
RP   SH-IPLA2).
RC   TISSUE=Pancreatic islet;
RX   PubMed=10092647; DOI=10.1074/jbc.274.14.9607;
RA   Ma Z., Wang X., Nowatzke W., Ramanadham S., Turk J.;
RT   "Human pancreatic islets express mRNA species encoding two distinct
RT   catalytically active isoforms of group VI phospholipase A2 (iPLA2)
RT   that arise from an exon-skipping mechanism of alternative splicing of
RT   the transcript from the iPLA2 gene on chromosome 22q13.1.";
RL   J. Biol. Chem. 274:9607-9616(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=10336645; DOI=10.1046/j.1432-1327.1999.00418.x;
RA   Larsson Forsell P.K.A., Kennedy B.P., Claesson H.-E.;
RT   "The human calcium-independent phospholipase A2 gene. Multiple enzymes
RT   with distinct properties from a single gene.";
RL   Eur. J. Biochem. 262:575-585(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LH-IPLA2).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LH-IPLA2).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-58; GLY-63;
RP   GLN-70; ASN-183 AND THR-343.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LH-IPLA2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LH-IPLA2 AND
RP   SH-IPLA2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION IN CHEMOTAXIS, AND SUBCELLULAR LOCATION.
RX   PubMed=18208975; DOI=10.1084/jem.20071243;
RA   Mishra R.S., Carnevale K.A., Cathcart M.K.;
RT   "iPLA2beta: front and center in human monocyte chemotaxis to MCP-1.";
RL   J. Exp. Med. 205:347-359(2008).
RN   [12]
RP   REVIEW ON FAMILY.
RX   PubMed=19029121; DOI=10.1194/jlr.R800082-JLR200;
RA   Kienesberger P.C., Oberer M., Lass A., Zechner R.;
RT   "Mammalian patatin domain containing proteins: a family with diverse
RT   lipolytic activities involved in multiple biological functions.";
RL   J. Lipid Res. 50:S63-S68(2009).
RN   [13]
RP   FUNCTION, AND PHARMACEUTICAL USE.
RX   PubMed=19164547; DOI=10.1073/pnas.0811224106;
RA   Malhotra A., Edelman-Novemsky I., Xu Y., Plesken H., Ma J.,
RA   Schlame M., Ren M.;
RT   "Role of calcium-independent phospholipase A2 in the pathogenesis of
RT   Barth syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2337-2341(2009).
RN   [14]
RP   VARIANT NBIA2A VAL-691 DEL.
RX   PubMed=17033970; DOI=10.1086/508572;
RA   Khateeb S., Flusser H., Ofir R., Shelef I., Narkis G., Vardi G.,
RA   Shorer Z., Levy R., Galil A., Elbedour K., Birk O.S.;
RT   "PLA2G6 mutation underlies infantile neuroaxonal dystrophy.";
RL   Am. J. Hum. Genet. 79:942-948(2006).
RN   [15]
RP   VARIANTS NBIA2B THR-545 AND TRP-632, AND VARIANTS NBIA2A GLU-310 AND
RP   VAL-691 DEL.
RX   PubMed=16783378; DOI=10.1038/ng1826;
RA   Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P.,
RA   Sonek S., Cangul H., Coryell J., Canham N., Nardocci N., Zorzi G.,
RA   Pasha S., Rodriguez D., Desguerre I., Mubaidin A., Bertini E.,
RA   Trembath R.C., Simonati A., Schanen C., Johnson C.A., Levinson B.,
RA   Woods C.G., Wilmot B., Kramer P., Gitschier J., Maher E.R.,
RA   Hayflick S.J.;
RT   "PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative
RT   disorders with high brain iron.";
RL   Nat. Genet. 38:752-754(2006).
RN   [16]
RP   ERRATUM.
RA   Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P.,
RA   Sonek S., Cangul H., Coryell J., Canham N., Nardocci N., Zorzi G.,
RA   Pasha S., Rodriguez D., Desguerre I., Mubaidin A., Bertini E.,
RA   Trembath R.C., Simonati A., Schanen C., Johnson C.A., Levinson B.,
RA   Woods C.G., Wilmot B., Kramer P., Gitschier J., Maher E.R.,
RA   Hayflick S.J.;
RL   Nat. Genet. 38:957-957(2006).
RN   [17]
RP   VARIANTS PARK14 GLN-741 AND TRP-747.
RX   PubMed=18570303; DOI=10.1002/ana.21415;
RA   Paisan-Ruiz C., Bhatia K.P., Li A., Hernandez D., Davis M., Wood N.W.,
RA   Hardy J., Houlden H., Singleton A., Schneider S.A.;
RT   "Characterization of PLA2G6 as a locus for dystonia-parkinsonism.";
RL   Ann. Neurol. 65:19-23(2009).
RN   [18]
RP   VARIANTS NBIA2A GLY-484 AND MET-661.
RX   PubMed=23749988; DOI=10.1136/jmedgenet-2013-101634;
RA   Koeroglu C., Seven M., Tolun A.;
RT   "Recessive truncating NALCN mutation in infantile neuroaxonal
RT   dystrophy with facial dysmorphism.";
RL   J. Med. Genet. 50:515-520(2013).
CC   -!- FUNCTION: Catalyzes the release of fatty acids from phospholipids.
CC       It has been implicated in normal phospholipid remodeling, nitric
CC       oxide-induced or vasopressin-induced arachidonic acid release and
CC       in leukotriene and prostaglandin production. May participate in
CC       fas mediated apoptosis and in regulating transmembrane ion flux in
CC       glucose-stimulated B-cells. Has a role in cardiolipin (CL)
CC       deacylation. Required for both speed and directionality of
CC       monocyte MCP1/CCL2-induced chemotaxis through regulation of F-
CC       actin polymerization at the pseudopods.
CC   -!- FUNCTION: Isoform ankyrin-iPLA2-1 and isoform ankyrin-iPLA2-2,
CC       which lack the catalytic domain, are probably involved in the
CC       negative regulation of iPLA2 activity.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
CC       acylglycerophosphocholine + a carboxylate.
CC   -!- ENZYME REGULATION: Inhibited by calcium-activated calmodulin.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Forms large oligomeric 270-350 kDa structures.
CC   -!- SUBCELLULAR LOCATION: Isoform LH-iPLA2: Membrane; Peripheral
CC       membrane protein. Note=Recruited to the membrane-enriched
CC       pseudopod upon MCP1/CCL2 stimulation in monocytes.
CC   -!- SUBCELLULAR LOCATION: Isoform SH-iPLA2: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=LH-iPLA2;
CC         IsoId=O60733-1; Sequence=Displayed;
CC       Name=SH-iPLA2;
CC         IsoId=O60733-2; Sequence=VSP_000278;
CC       Name=Ankyrin-iPLA2-1;
CC         IsoId=O60733-3; Sequence=VSP_000281, VSP_000282;
CC       Name=Ankyrin-iPLA2-2;
CC         IsoId=O60733-4; Sequence=VSP_000277, VSP_000279, VSP_000280;
CC   -!- TISSUE SPECIFICITY: Four different transcripts were found to be
CC       expressed in a distinct tissue distribution.
CC   -!- DISEASE: Neurodegeneration with brain iron accumulation 2B
CC       (NBIA2B) [MIM:610217]: A neurodegenerative disorder associated
CC       with iron accumulation in the brain, primarily in the basal
CC       ganglia. It is characterized by progressive extrapyramidal
CC       dysfunction leading to rigidity, dystonia, dysarthria and
CC       sensorimotor impairment. {ECO:0000269|PubMed:16783378}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Neurodegeneration with brain iron accumulation 2A
CC       (NBIA2A) [MIM:256600]: A neurodegenerative disease characterized
CC       by pathologic axonal swelling and spheroid bodies in the central
CC       nervous system. Onset is within the first 2 years of life with
CC       death by age 10 years. {ECO:0000269|PubMed:16783378,
CC       ECO:0000269|PubMed:17033970, ECO:0000269|PubMed:23749988}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Parkinson disease 14 (PARK14) [MIM:612953]: An adult-
CC       onset progressive neurodegenerative disorder characterized by
CC       parkinsonism, dystonia, severe cognitive decline, cerebral and
CC       cerebellar atrophy and absent iron in the basal ganglia on
CC       magnetic resonance imaging. {ECO:0000269|PubMed:18570303}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- PHARMACEUTICAL: Potential target for therapeutic intervention of
CC       Barth syndrome.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pla2g6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF064594; AAC97486.1; -; mRNA.
DR   EMBL; AF102988; AAD41722.1; -; mRNA.
DR   EMBL; AF102989; AAD41723.1; -; mRNA.
DR   EMBL; AF117692; AAD30424.1; -; Genomic_DNA.
DR   EMBL; AF117677; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117678; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117679; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117680; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117681; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117682; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117683; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117684; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117685; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117686; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117687; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117688; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117689; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117690; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF117691; AAD30424.1; JOINED; Genomic_DNA.
DR   EMBL; AF116267; AAF34728.1; -; Genomic_DNA.
DR   EMBL; AF116252; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116253; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116254; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116255; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116256; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116257; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116258; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116259; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116260; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116261; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116262; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116263; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116264; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116265; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AF116266; AAF34728.1; JOINED; Genomic_DNA.
DR   EMBL; AL080187; CAB45768.2; -; mRNA.
DR   EMBL; CR456543; CAG30429.1; -; mRNA.
DR   EMBL; AY522921; AAR92478.1; -; Genomic_DNA.
DR   EMBL; AK291212; BAF83901.1; -; mRNA.
DR   EMBL; AL022322; CAA18446.1; -; Genomic_DNA.
DR   EMBL; AL022322; CAQ10446.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60219.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60220.1; -; Genomic_DNA.
DR   EMBL; BC036742; AAH36742.2; -; mRNA.
DR   EMBL; BC051904; AAH51904.1; -; mRNA.
DR   CCDS; CCDS13967.1; -. [O60733-1]
DR   CCDS; CCDS33645.1; -. [O60733-2]
DR   RefSeq; NP_001004426.1; NM_001004426.1. [O60733-2]
DR   RefSeq; NP_001186491.1; NM_001199562.1. [O60733-2]
DR   RefSeq; NP_003551.2; NM_003560.2. [O60733-1]
DR   RefSeq; XP_005261821.1; XM_005261764.2. [O60733-1]
DR   RefSeq; XP_005261822.1; XM_005261765.1. [O60733-1]
DR   RefSeq; XP_005261823.1; XM_005261766.1. [O60733-1]
DR   RefSeq; XP_006724395.1; XM_006724332.3. [O60733-1]
DR   RefSeq; XP_016884470.1; XM_017028981.1. [O60733-2]
DR   RefSeq; XP_016884471.1; XM_017028982.1. [O60733-2]
DR   RefSeq; XP_016884477.1; XM_017028988.1. [O60733-3]
DR   UniGene; Hs.170479; -.
DR   ProteinModelPortal; O60733; -.
DR   SMR; O60733; -.
DR   BioGrid; 113986; 4.
DR   IntAct; O60733; 11.
DR   STRING; 9606.ENSP00000333142; -.
DR   BindingDB; O60733; -.
DR   ChEMBL; CHEMBL3213; -.
DR   DrugBank; DB01103; Quinacrine.
DR   SwissLipids; SLP:000000618; -.
DR   iPTMnet; O60733; -.
DR   PhosphoSitePlus; O60733; -.
DR   BioMuta; PLA2G6; -.
DR   EPD; O60733; -.
DR   MaxQB; O60733; -.
DR   PaxDb; O60733; -.
DR   PeptideAtlas; O60733; -.
DR   PRIDE; O60733; -.
DR   DNASU; 8398; -.
DR   Ensembl; ENST00000332509; ENSP00000333142; ENSG00000184381. [O60733-1]
DR   Ensembl; ENST00000335539; ENSP00000335149; ENSG00000184381. [O60733-2]
DR   Ensembl; ENST00000402064; ENSP00000386100; ENSG00000184381. [O60733-2]
DR   GeneID; 8398; -.
DR   KEGG; hsa:8398; -.
DR   UCSC; uc003auy.2; human. [O60733-1]
DR   CTD; 8398; -.
DR   DisGeNET; 8398; -.
DR   GeneCards; PLA2G6; -.
DR   GeneReviews; PLA2G6; -.
DR   HGNC; HGNC:9039; PLA2G6.
DR   HPA; HPA001171; -.
DR   MalaCards; PLA2G6; -.
DR   MIM; 256600; phenotype.
DR   MIM; 603604; gene.
DR   MIM; 610217; phenotype.
DR   MIM; 612953; phenotype.
DR   neXtProt; NX_O60733; -.
DR   OpenTargets; ENSG00000184381; -.
DR   Orphanet; 199351; Adult-onset dystonia-parkinsonism.
DR   Orphanet; 35069; Infantile neuroaxonal dystrophy.
DR   PharmGKB; PA33367; -.
DR   eggNOG; KOG0513; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   eggNOG; COG3621; LUCA.
DR   GeneTree; ENSGT00530000063645; -.
DR   HOVERGEN; HBG053482; -.
DR   InParanoid; O60733; -.
DR   KO; K16343; -.
DR   OMA; KEDMVRS; -.
DR   OrthoDB; EOG091G042U; -.
DR   PhylomeDB; O60733; -.
DR   TreeFam; TF319230; -.
DR   BRENDA; 3.1.1.4; 2681.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482798; Acyl chain remodeling of CL.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-6811436; COPI-independent Golgi-to-ER retrograde traffic.
DR   ChiTaRS; PLA2G6; human.
DR   GeneWiki; PLA2G6; -.
DR   GenomeRNAi; 8398; -.
DR   PMAP-CutDB; O60733; -.
DR   PRO; PR:O60733; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000184381; -.
DR   CleanEx; HS_PLA2G6; -.
DR   ExpressionAtlas; O60733; baseline and differential.
DR   Genevisible; O60733; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043008; F:ATP-dependent protein binding; IEA:Ensembl.
DR   GO; GO:0047499; F:calcium-independent phospholipase A2 activity; IEA:Ensembl.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0016787; F:hydrolase activity; TAS:Reactome.
DR   GO; GO:0004623; F:phospholipase A2 activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0032049; P:cardiolipin biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; IEA:Ensembl.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:2000304; P:positive regulation of ceramide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IEA:Ensembl.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:1901339; P:regulation of store-operated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IEA:Ensembl.
DR   Gene3D; 1.25.40.20; -; 3.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR002641; PNPLA_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF01734; Patatin; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 6.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF52151; SSF52151; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS51635; PNPLA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ANK repeat; Calmodulin-binding; Chemotaxis;
KW   Complete proteome; Cytoplasm; Disease mutation; Dystonia; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Membrane; Neurodegeneration;
KW   Parkinsonism; Pharmaceutical; Polymorphism; Reference proteome;
KW   Repeat.
FT   CHAIN         1    806       85/88 kDa calcium-independent
FT                                phospholipase A2.
FT                                /FTId=PRO_0000067037.
FT   REPEAT      151    181       ANK 1.
FT   REPEAT      185    215       ANK 2.
FT   REPEAT      219    248       ANK 3.
FT   REPEAT      251    281       ANK 4.
FT   REPEAT      286    312       ANK 5.
FT   REPEAT      316    345       ANK 6.
FT   REPEAT      349    378       ANK 7.
FT   DOMAIN      481    665       PNPLA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   REGION      677    696       Calmodulin-binding. {ECO:0000250}.
FT   REGION      748    759       Calmodulin-binding. {ECO:0000250}.
FT   MOTIF       485    490       GXGXXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF       517    521       GXSXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF       652    654       DGA/G. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE    519    519       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE    652    652       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   VAR_SEQ      71    142       Missing (in isoform Ankyrin-iPLA2-2).
FT                                {ECO:0000303|PubMed:9417066}.
FT                                /FTId=VSP_000277.
FT   VAR_SEQ     396    450       LVTRKAILTLLRTVGAEYCFPPIHGVPAEQGSAAPHHPFSL
FT                                ERAQPPPISLNNLE -> Q (in isoform SH-
FT                                iPLA2). {ECO:0000303|PubMed:10092647,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000278.
FT   VAR_SEQ     450    499       ELQDLMHISRARKPAFILGSMRDEKRTHDHLLCLDGGGVKG
FT                                LIIIQLLIA -> GSHPSQAGWWAWGAVSDGTTGSHAHLTG
FT                                PEASVHPGLHEGREADMQNLSP (in isoform
FT                                Ankyrin-iPLA2-2).
FT                                {ECO:0000303|PubMed:9417066}.
FT                                /FTId=VSP_000279.
FT   VAR_SEQ     477    479       HDH -> CRT (in isoform Ankyrin-iPLA2-1).
FT                                {ECO:0000303|PubMed:9417066}.
FT                                /FTId=VSP_000281.
FT   VAR_SEQ     480    806       Missing (in isoform Ankyrin-iPLA2-1).
FT                                {ECO:0000303|PubMed:9417066}.
FT                                /FTId=VSP_000282.
FT   VAR_SEQ     500    806       Missing (in isoform Ankyrin-iPLA2-2).
FT                                {ECO:0000303|PubMed:9417066}.
FT                                /FTId=VSP_000280.
FT   VARIANT      58     58       V -> I (in dbSNP:rs11570605).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018961.
FT   VARIANT      63     63       R -> G (in dbSNP:rs11570606).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018962.
FT   VARIANT      70     70       R -> Q (in dbSNP:rs11570607).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018963.
FT   VARIANT     183    183       D -> N (in dbSNP:rs11570646).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018964.
FT   VARIANT     310    310       V -> E (in NBIA2A; dbSNP:rs121908682).
FT                                {ECO:0000269|PubMed:16783378}.
FT                                /FTId=VAR_029371.
FT   VARIANT     343    343       A -> T (in dbSNP:rs11570680).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018965.
FT   VARIANT     484    484       D -> G (in NBIA2A).
FT                                {ECO:0000269|PubMed:23749988}.
FT                                /FTId=VAR_070600.
FT   VARIANT     545    545       K -> T (in NBIA2B; dbSNP:rs121908681).
FT                                {ECO:0000269|PubMed:16783378}.
FT                                /FTId=VAR_029372.
FT   VARIANT     632    632       R -> W (in NBIA2B; dbSNP:rs121908683).
FT                                {ECO:0000269|PubMed:16783378}.
FT                                /FTId=VAR_029373.
FT   VARIANT     661    661       T -> M (in NBIA2A; dbSNP:rs767689496).
FT                                {ECO:0000269|PubMed:23749988}.
FT                                /FTId=VAR_070601.
FT   VARIANT     691    691       Missing (in NBIA2A).
FT                                {ECO:0000269|PubMed:16783378,
FT                                ECO:0000269|PubMed:17033970}.
FT                                /FTId=VAR_029374.
FT   VARIANT     741    741       R -> Q (in PARK14; dbSNP:rs121908686).
FT                                {ECO:0000269|PubMed:18570303}.
FT                                /FTId=VAR_062530.
FT   VARIANT     747    747       R -> W (in PARK14; dbSNP:rs121908687).
FT                                {ECO:0000269|PubMed:18570303}.
FT                                /FTId=VAR_062531.
FT   VARIANT     774    774       S -> T (in dbSNP:rs34184838).
FT                                /FTId=VAR_037903.
FT   CONFLICT     11     11       F -> S (in Ref. 3; AAD30424).
FT                                {ECO:0000305}.
FT   CONFLICT     64     64       N -> D (in Ref. 2; AAD41722/AAD41723).
FT                                {ECO:0000305}.
FT   CONFLICT    579    579       K -> I (in Ref. 3; AAD30424).
FT                                {ECO:0000305}.
FT   CONFLICT    686    686       K -> I (in Ref. 3; AAD30424).
FT                                {ECO:0000305}.
FT   CONFLICT    801    801       Q -> H (in Ref. 1; AAC97486).
FT                                {ECO:0000305}.
SQ   SEQUENCE   806 AA;  89903 MW;  8E55CD4EB9ACAD8B CRC64;
     MQFFGRLVNT FSGVTNLFSN PFRVKEVAVA DYTSSDRVRE EGQLILFQNT PNRTWDCVLV
     NPRNSQSGFR LFQLELEADA LVNFHQYSSQ LLPFYESSPQ VLHTEVLQHL TDLIRNHPSW
     SVAHLAVELG IRECFHHSRI ISCANCAENE EGCTPLHLAC RKGDGEILVE LVQYCHTQMD
     VTDYKGETVF HYAVQGDNSQ VLQLLGRNAV AGLNQVNNQG LTPLHLACQL GKQEMVRVLL
     LCNARCNIMG PNGYPIHSAM KFSQKGCAEM IISMDSSQIH SKDPRYGASP LHWAKNAEMA
     RMLLKRGCNV NSTSSAGNTA LHVAVMRNRF DCAIVLLTHG ANADARGEHG NTPLHLAMSK
     DNVEMIKALI VFGAEVDTPN DFGETPTFLA SKIGRLVTRK AILTLLRTVG AEYCFPPIHG
     VPAEQGSAAP HHPFSLERAQ PPPISLNNLE LQDLMHISRA RKPAFILGSM RDEKRTHDHL
     LCLDGGGVKG LIIIQLLIAI EKASGVATKD LFDWVAGTST GGILALAILH SKSMAYMRGM
     YFRMKDEVFR GSRPYESGPL EEFLKREFGE HTKMTDVRKP KVMLTGTLSD RQPAELHLFR
     NYDAPETVRE PRFNQNVNLR PPAQPSDQLV WRAARSSGAA PTYFRPNGRF LDGGLLANNP
     TLDAMTEIHE YNQDLIRKGQ ANKVKKLSIV VSLGTGRSPQ VPVTCVDVFR PSNPWELAKT
     VFGAKELGKM VVDCCTDPDG RAVDRARAWC EMVGIQYFRL NPQLGTDIML DEVSDTVLVN
     ALWETEVYIY EHREEFQKLI QLLLSP
//
